Navigation Links
Doubt Cast on Use of Genetic Test Before Plavix
Date:12/28/2011

WEDNESDAY, Dec. 28 (HealthDay News) -- A new review of existing research suggests that, despite a federal recommendation, genetic testing won't help physicians determine which heart patients should get Plavix, a blood-thinning drug used to treat certain cardiac conditions.

Plavix, also known as clopidogrel, is used to treat or prevent blood clots due to the clogging of arteries and after such surgical procedures as balloon angioplasty.

But some patients won't experience the drug's clot-preventing benefits if their bodies don't process it properly, potentially leading to heart attack, blood clots in stents and death, according to Dr. Jean-Sebastien Hulot, associate professor of medicine at the Cardiovascular Research Center at Mount Sinai School of Medicine. Or, he said, they could experience the reverse -- excessive bleeding if the medication has too much of an effect. Hulot was not involved with the study, but is familiar with the findings.

The U.S. Food and Drug Administration believes that genetic testing could help identify patients who won't respond well to the drug. But the American Heart Association and the American College of Cardiologists have been skeptical that the genetic testing in question is useful.

In the new review, Dr. Michael V. Holmes of University College London and colleagues examined 32 studies that included over 42,000 patients. They looked for signs of bleeding problems, blood clots in stents and cardiovascular problems.

They also conducted a meta-analysis in which they examined statistics in the studies as a whole.

While they mention some statistical caveats, the researchers found that a specific genetic trait -- linked to the body's ability to respond to the drug -- did not significantly affect the risk of cardiovascular problems.

In a commentary accompanying the study, Dr. Steven E. Nissen, borrowing a phrase from a former chairman of the Federal Reserve, wrote, "It now appears that the FDA warning reflected a case of 'irrational exuberance.'"

Nissen, chair of cardiovascular medicine at the Cleveland Clinic, noted that the review has limitations. But, he added, for the time being physicians should "rarely, if ever" use the genetic testing in question and should "interpret the results with caution."

Hulot, the Mount Sinai School of Medicine professor, is skeptical. He said the findings are "far from convincing" and questioned their statistical validity. He also pointed to an earlier study, also a meta-analysis, that suggested a genetic trait did indeed boost the risk of problems for those who took the drug in certain cases.

The study is published in the Dec. 28 issue of the Journal of the American Medical Association.

More information

For more on Plavix (clopidogrel), visit the U.S. National Library of Medicine.

-- Randy Dotinga

SOURCES: Jean-Sebastien Hulot, M.D., Ph.D., associate professor of medicine and director, Pharmacogenomics & Personalized Therapeutics, Cardiovascular Research Center, Mount Sinai School of Medicine, New York City; Dec. 28, 2011, Journal of the American Medical Association


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Study Casts Doubt on Hospice Admission Criteria for Patients With Dementia
2. Lifesaving antibiotics face doubtful future
3. Intensive care nurses have doubts about method for establishing brain death
4. New Report Casts More Doubt on Virus Link to Chronic Fatigue Syndrome
5. Study Casts Doubt on Hot Dogs Link to Colon Cancer
6. Requests for Alzheimers disease research grants up by 33 percent, as federal funding in doubt
7. Certain genetic profiles associated with recurrence-free survival for non-small cell lung cancer
8. Obstructive Sleep Apnea in Kids May Have Genetic Cause
9. Epigenetic signals differ across alleles
10. Study reveals genetic link between mammographic density and breast cancer
11. Genetic Risk Score Doesnt Spot Heart Trouble in Women
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Doubt Cast on Use of Genetic Test Before Plavix
(Date:8/20/2017)... ... August 20, 2017 , ... Are you an adult ... If so, you may be interested in participating in a research study that ... research is to understand more about the relational aspects of adults who have gluten ...
(Date:8/19/2017)... (PRWEB) , ... August 19, 2017 , ... ... announced that it is the first organization with pending recognition status from the ... Prevention Program (“DPP”) via group telehealth classes and live video conferencing. , ...
(Date:8/19/2017)... ... August 19, 2017 , ... Physician Partners of America ... as an interventional pain management physician. He brings a wealth of pain management ... headaches, and significant experience in spinal cord stimulation for chronic pain. , Dr. ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... specialized asset-light logistics provider of complex transport solutions for mission-critical and non-discretionary ... Unitrans International Corporation, a division of Roadrunner Transportation Systems, Inc. (NYSE: RRTS). ...
(Date:8/18/2017)... ... ... The Dawn Johnson Insurance Group, a Missouri-based insurance and financial planning firm ... for efforts to educate the local population on cancer realities while attracting donations to ... , Each day in America, roughly 4,600 new cases of cancer are diagnosed and ...
Breaking Medicine News(10 mins):
(Date:8/17/2017)... Bio-Ess Laboratories, LLC Chief Science Officer, Dr. Adam Elhofy ... data on Cell-Ess® Universal Titer Boost at the 9 th ... August 21-25.  The Bioprocessing Summit convenes more than 1,000 international bioprocess ... ... Cell-Ess ...
(Date:8/15/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO), is now ... residents. Naloxone is available without a ... pharmacy, G-3320 Beecher Road. ... Administration, is intended to block or reverse the effects ... of consciousness. The medication is often carried by first ...
(Date:8/15/2017)... N.C. , Aug. 15, 2017 AccuGenomics, ... NC , today announced that the company has ... the University of North Carolina at Chapel Hill and ... is designed to characterize and quantify HIV reservoir and ... after pharmacological intervention. The HIV Cure Center is a ...
Breaking Medicine Technology: